Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.60 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | WDR5 | P61964 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.60 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.60 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.60 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.60 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.60 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lansoprazole SCHEMBL17956714 | 1.00 | CYP2C9 (0.62) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29358567 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29750802 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29950208 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29353881 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1559598 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL44975 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29598842 | 0.99 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530954-A | Polycyclic ketone monooxygenase mutant and application thereof in chiral azole drug synthesis | 福州大学 | 2024-08-23 | — | — | CN | claimed |
| US-20220016099-A1 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | TRINUERO (KR) | 2022-01-20 | — | — | US | claimed |
| CN-113582973-A | Preparation method of thioether | 丽珠医药集团股份有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-112939941-A | Preparation method of lansoprazole | 珠海润都制药股份有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-109467527-B | Tartrate thioester compound and preparation method and application thereof | 江苏奥赛康药业有限公司 | 2021-04-06 | — | — | CN | claimed |
| WO-2020116742-A1 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | 주식회사 트리뉴로 | 2020-06-11 | — | — | WO | claimed |
| CN-110545815-A | Medical application of cytochrome bc1 compound inhibitor | BEIJING WEILANZHIYUAN MEDICAL TECH CO LTD | 2019-12-06 | — | — | CN | claimed |
| CN-107365300-B | A method of effectively removing impurity in Lansoprazole crude product | 桂林华信制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-109467527-A | Tartaric acid sulfur ester and its preparation method and application | 江苏奥赛康药业股份有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-107556290-A | A kind of Lansoprazole thioether monohydrate structure cell and preparation method thereof | 陕西合成药业股份有限公司 | 2018-01-09 | — | — | CN | claimed |
| CN-107365300-A | A kind of method for effectively removing impurity in Lansoprazole crude product | 桂林华信制药有限公司 | 2017-11-21 | — | — | CN | claimed |
| CN-106946849-A | A kind of R-lansoprazole and preparation method thereof and purposes | 乐普药业科技有限公司 | 2017-07-14 | — | — | CN | claimed |
| EP-2521531-B1 | SKIN LIGHTENING COMPOSITIONS | ELC MAN LLC (US) | 2017-07-12 | — | — | EP | claimed |
| CN-106518847-A | Oxidation method for Dexlansoprazole | 李景丕 | 2017-03-22 | — | — | CN | claimed |
| WO-2008001392-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PANTOPRAZOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2008-01-03 | — | — | WO | claimed |
| WO-2007138468-A2 | PROCESSES FOR THE PREPARATION OF LANSOPRAZOLE | WOCKHARDT LTD (IN) | 2007-12-06 | — | — | WO | claimed |
| CN-118530954-A | Polycyclic ketone monooxygenase mutant and application thereof in chiral azole drug synthesis | 福州大学 | 2024-08-23 | — | — | CN | disclosed |
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | DISARM THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2004080440-A1 | PROCESS FOR THE PREPARING OF HARDCAPSULE FORMULATION CONTAINING LANSOPRAZOLE | KOREA UNITED PHARM, INC. (KR) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056803-A1 | PROCESS FOR THE PREPARATION OF SULPHINYL DERIVATIVES BY OXIDATION OF THE CORRESPONDING SULFIDES | CHEMI SPA (IT) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238264-A1 | INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF | SARM1, NADK, NNMT | ATP4A 3164/4885ATP4B 3335/4885CYP2C9 4424/4885 |
| US-20220016099-A1 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | KEAP1, SLC5A1, GCLC | ATP4A 484/4885ATP4B 844/4885CYP2C9 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.